Image & Video

7 Tesla MRI + ML achieves 100% accuracy in Parkinson's motor subtype stratification

Deep learning on ultra-high field MRI perfectly distinguishes tremor-dominant from gait-impaired Parkinson's...

Deep Dive

A team led by Anne Louise Kristoffersen at the Norwegian University of Science and Technology applied 7 Tesla quantitative MRI combined with machine learning to objectively stratify Parkinson's disease motor subtypes. They included 24 people with PD (PwP) and 21 healthy controls, classifying them into Healthy Controls (HC), Postural Instability and Gait Difficulty (PIGD), and Tremor Dominant (TD). A U-Net deep learning model performed automatic brain segmentation, achieving a mean Dice Similarity Coefficient of 0.86 across all regions of interest. Using two classification approaches—one with all extracted features and one with optimized feature selection via machine learning—the team tested three tasks: HC vs PwP, PIGD vs TD, and multiclass (HC vs PIGD vs TD).

With feature selection (Approach B), performance soared: HC vs PwP reached 82% accuracy (AUC 0.93), PIGD vs TD achieved 100% accuracy (AUC 1.00), and the multiclass task hit 73% accuracy (AUC 0.91)—all dramatically better than using all features (Approach A: 69%, 69%, 62% respectively). The authors emphasize that low-dimensional, interpretable imaging signatures from 7T qMRI can support objective PD diagnosis and phenotype stratification. They note that larger multi-site studies are needed to validate generalizability. The work opens the door for precision medicine in Parkinson's, enabling tailored treatments based on motor subtype imaging biomarkers.

Key Points
  • U-Net segmentation on 7T MRI achieved a mean DSC of 0.86 across all brain ROIs, enabling reliable feature extraction for classification.
  • Feature selection improved PIGD vs TD classification from 69% accuracy to 100% (AUC 1.00), and healthy vs PD from 69% to 82% (AUC 0.93).
  • Multiclass task (HC vs PIGD vs TD) reached 73% accuracy with feature selection vs 62% without, showing potential for objective subtype stratification.

Why It Matters

Personalized Parkinson's treatment and clinical trial design could be revolutionized by objective, MRI-based subtype stratification instead of subjective clinical assessment.